152 related articles for article (PubMed ID: 8474480)
21. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
[TBL] [Abstract][Full Text] [Related]
22. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
23. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
24. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
Blanchet PJ; Calon F; Martel JC; Bédard PJ; Di Paolo T; Walters RR; Piercey MF
J Pharmacol Exp Ther; 1995 Feb; 272(2):854-9. PubMed ID: 7853204
[TBL] [Abstract][Full Text] [Related]
25. Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.
Luquin MR; Guillén J; Martínez-Vila E; Laguna J; Martínez-Lage JM
Eur J Pharmacol; 1994 Mar; 253(3):215-24. PubMed ID: 7911084
[TBL] [Abstract][Full Text] [Related]
26. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
Temlett JA; Quinn NP; Jenner PG; Marsden CD; Pourcher E; Bonnet AM; Agid Y; Markstein R; Lataste X
Mov Disord; 1989; 4(3):261-5. PubMed ID: 2571082
[TBL] [Abstract][Full Text] [Related]
27. Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine.
Sprah L; Zivin M; Sket D
J Pharmacol Exp Ther; 1999 Mar; 288(3):1093-100. PubMed ID: 10027846
[TBL] [Abstract][Full Text] [Related]
28. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.
Vermeulen RJ; Drukarch B; Sahadat MC; Goosen C; Wolters EC; Stoof JC
Mov Disord; 1994 Nov; 9(6):664-72. PubMed ID: 7845408
[TBL] [Abstract][Full Text] [Related]
29. MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
Schneider JS
J Neurosci Res; 1992 Jan; 31(1):112-9. PubMed ID: 1613817
[TBL] [Abstract][Full Text] [Related]
30. Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.
Graybiel AM; Moratalla R; Quinn B; DeLanney LE; Irwin I; Langston JW
Adv Neurol; 1993; 60():34-9. PubMed ID: 8420148
[No Abstract] [Full Text] [Related]
31. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
Pope-Coleman A; Tinker JP; Schneider JS
Synapse; 2000 May; 36(2):120-8. PubMed ID: 10767059
[TBL] [Abstract][Full Text] [Related]
32. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Goulet M; Madras BK
J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
[TBL] [Abstract][Full Text] [Related]
33. Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft.
San Sebastián W; Guillén J; Manrique M; Belzunegui S; Ciordia E; Izal-Azcárate A; Garrido-Gil P; Vázquez-Claverie M; Luquin MR
Brain; 2007 May; 130(Pt 5):1306-16. PubMed ID: 17439984
[TBL] [Abstract][Full Text] [Related]
34. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
35. Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.
Calon F; Lavertu N; Lemieux AM; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Synapse; 2001 Jun; 40(3):225-34. PubMed ID: 11304760
[TBL] [Abstract][Full Text] [Related]
36. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
37. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Falardeau P; Bouchard S; Bédard PJ; Boucher R; Di Paolo T
Eur J Pharmacol; 1988 May; 150(1-2):59-66. PubMed ID: 3261249
[TBL] [Abstract][Full Text] [Related]
38. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
[TBL] [Abstract][Full Text] [Related]
39. Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.
Muriel MP; Orieux G; Hirsch EC
Mov Disord; 2002 Nov; 17(6):1174-9. PubMed ID: 12465054
[TBL] [Abstract][Full Text] [Related]
40. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys.
Luquin MR; Laguna J; Obeso JA
Ann Neurol; 1992 May; 31(5):551-4. PubMed ID: 1350718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
